vs

Side-by-side financial comparison of NICOLET BANKSHARES INC (NIC) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $104.0M, roughly 1.5× NICOLET BANKSHARES INC). NICOLET BANKSHARES INC runs the higher net margin — 38.8% vs -5.5%, a 44.3% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 12.5%). NICOLET BANKSHARES INC produced more free cash flow last quarter ($149.4M vs $13.0M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 12.5%).

Nicolet Bankshares, Inc. is a U.S. regional bank holding company based in Green Bay, Wisconsin. They are the parent company of Nicolet National Bank, the second largest Wisconsin-based bank.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

NIC vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.5× larger
TARS
$151.7M
$104.0M
NIC
Growing faster (revenue YoY)
TARS
TARS
+115.9% gap
TARS
128.4%
12.5%
NIC
Higher net margin
NIC
NIC
44.3% more per $
NIC
38.8%
-5.5%
TARS
More free cash flow
NIC
NIC
$136.5M more FCF
NIC
$149.4M
$13.0M
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
12.5%
NIC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
NIC
NIC
TARS
TARS
Revenue
$104.0M
$151.7M
Net Profit
$40.3M
$-8.4M
Gross Margin
Operating Margin
48.3%
-5.3%
Net Margin
38.8%
-5.5%
Revenue YoY
12.5%
128.4%
Net Profit YoY
16.9%
63.8%
EPS (diluted)
$2.63
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NIC
NIC
TARS
TARS
Q4 25
$104.0M
$151.7M
Q3 25
$102.9M
$118.7M
Q2 25
$95.7M
$102.7M
Q1 25
$89.4M
$78.3M
Q4 24
$92.4M
$66.4M
Q3 24
$90.7M
$48.1M
Q2 24
$85.0M
$40.8M
Q1 24
$82.2M
$27.6M
Net Profit
NIC
NIC
TARS
TARS
Q4 25
$40.3M
$-8.4M
Q3 25
$41.7M
$-12.6M
Q2 25
$36.0M
$-20.3M
Q1 25
$32.6M
$-25.1M
Q4 24
$34.5M
$-23.1M
Q3 24
$32.5M
$-23.4M
Q2 24
$29.3M
$-33.3M
Q1 24
$27.8M
$-35.7M
Operating Margin
NIC
NIC
TARS
TARS
Q4 25
48.3%
-5.3%
Q3 25
50.4%
-12.2%
Q2 25
46.8%
-21.6%
Q1 25
44.9%
-33.5%
Q4 24
46.8%
-36.8%
Q3 24
45.0%
-52.3%
Q2 24
43.3%
-81.6%
Q1 24
41.8%
-136.5%
Net Margin
NIC
NIC
TARS
TARS
Q4 25
38.8%
-5.5%
Q3 25
40.6%
-10.6%
Q2 25
37.6%
-19.8%
Q1 25
36.4%
-32.1%
Q4 24
37.3%
-34.8%
Q3 24
35.8%
-48.7%
Q2 24
34.5%
-81.6%
Q1 24
33.8%
-129.4%
EPS (diluted)
NIC
NIC
TARS
TARS
Q4 25
$2.63
$-0.17
Q3 25
$2.73
$-0.30
Q2 25
$2.34
$-0.48
Q1 25
$2.08
$-0.64
Q4 24
$2.21
$-0.57
Q3 24
$2.10
$-0.61
Q2 24
$1.92
$-0.88
Q1 24
$1.82
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NIC
NIC
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$417.3M
Total DebtLower is stronger
$134.9M
$72.4M
Stockholders' EquityBook value
$1.3B
$343.4M
Total Assets
$9.2B
$562.2M
Debt / EquityLower = less leverage
0.11×
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NIC
NIC
TARS
TARS
Q4 25
$417.3M
Q3 25
$401.8M
Q2 25
$381.1M
Q1 25
$407.9M
Q4 24
$291.4M
Q3 24
$317.0M
Q2 24
$323.6M
Q1 24
$298.5M
Total Debt
NIC
NIC
TARS
TARS
Q4 25
$134.9M
$72.4M
Q3 25
$134.6M
$72.3M
Q2 25
$134.3M
$72.1M
Q1 25
$156.6M
$72.0M
Q4 24
$161.4M
$71.8M
Q3 24
$161.2M
$71.7M
Q2 24
$162.4M
$71.6M
Q1 24
$162.3M
$29.9M
Stockholders' Equity
NIC
NIC
TARS
TARS
Q4 25
$1.3B
$343.4M
Q3 25
$1.2B
$335.1M
Q2 25
$1.2B
$332.6M
Q1 25
$1.2B
$342.5M
Q4 24
$1.2B
$224.5M
Q3 24
$1.1B
$237.5M
Q2 24
$1.1B
$252.2M
Q1 24
$1.1B
$275.2M
Total Assets
NIC
NIC
TARS
TARS
Q4 25
$9.2B
$562.2M
Q3 25
$9.0B
$534.6M
Q2 25
$8.9B
$495.0M
Q1 25
$9.0B
$500.8M
Q4 24
$8.8B
$377.0M
Q3 24
$8.6B
$376.3M
Q2 24
$8.6B
$376.8M
Q1 24
$8.4B
$349.3M
Debt / Equity
NIC
NIC
TARS
TARS
Q4 25
0.11×
0.21×
Q3 25
0.11×
0.22×
Q2 25
0.11×
0.22×
Q1 25
0.13×
0.21×
Q4 24
0.14×
0.32×
Q3 24
0.14×
0.30×
Q2 24
0.15×
0.28×
Q1 24
0.15×
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NIC
NIC
TARS
TARS
Operating Cash FlowLast quarter
$153.5M
$19.3M
Free Cash FlowOCF − Capex
$149.4M
$13.0M
FCF MarginFCF / Revenue
143.7%
8.6%
Capex IntensityCapex / Revenue
3.9%
4.2%
Cash ConversionOCF / Net Profit
3.81×
TTM Free Cash FlowTrailing 4 quarters
$275.0M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NIC
NIC
TARS
TARS
Q4 25
$153.5M
$19.3M
Q3 25
$45.9M
$18.3M
Q2 25
$38.9M
$-29.4M
Q1 25
$41.8M
$-20.7M
Q4 24
$133.7M
$-22.2M
Q3 24
$39.6M
$-8.7M
Q2 24
$37.3M
$-14.4M
Q1 24
$23.4M
$-37.8M
Free Cash Flow
NIC
NIC
TARS
TARS
Q4 25
$149.4M
$13.0M
Q3 25
$45.9M
$16.3M
Q2 25
$38.4M
$-30.4M
Q1 25
$41.3M
$-21.2M
Q4 24
$116.8M
$-22.3M
Q3 24
$34.7M
$-8.9M
Q2 24
$34.4M
$-15.4M
Q1 24
$20.1M
$-38.0M
FCF Margin
NIC
NIC
TARS
TARS
Q4 25
143.7%
8.6%
Q3 25
44.6%
13.8%
Q2 25
40.1%
-29.6%
Q1 25
46.2%
-27.1%
Q4 24
126.4%
-33.5%
Q3 24
38.3%
-18.6%
Q2 24
40.5%
-37.8%
Q1 24
24.4%
-137.5%
Capex Intensity
NIC
NIC
TARS
TARS
Q4 25
3.9%
4.2%
Q3 25
0.0%
1.6%
Q2 25
0.6%
1.0%
Q1 25
0.5%
0.8%
Q4 24
18.3%
0.1%
Q3 24
5.4%
0.6%
Q2 24
3.5%
2.5%
Q1 24
4.0%
0.6%
Cash Conversion
NIC
NIC
TARS
TARS
Q4 25
3.81×
Q3 25
1.10×
Q2 25
1.08×
Q1 25
1.28×
Q4 24
3.88×
Q3 24
1.22×
Q2 24
1.28×
Q1 24
0.84×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons